-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $4

Benzinga·02/06/2026 15:48:59
Listen to the news
Piper Sandler analyst Allison Bratzel maintains Akebia Therapeutics (NASDAQ:AKBA) with a Overweight and lowers the price target from $6 to $4.